Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.
April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy
Oral Zasocitinib Demonstrates Safety and Efficacy in Moderate to Severe Plaque Psoriasis